All sponsors

BeiGene $ONC

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING1
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO75%

Delay Index: of 8 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +8.8 months). See all sponsors →

Open BeiGene on the live radar map → 📅 $ONC readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SEQUOIA
NCT03336333
P3Active, not recruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma5902021-05-07 (+8 mo)
Tislelizumab
NCT04379635
P3Active, not recruitingNon Small Cell Lung Cancer4532023-08-21 (+7 mo)
BGB-11417
NCT05479994
P2Active, not recruitingLeukemia; Lymphoma1002025-01-24 (+4 mo)
Alcestobart
NCT05609370
P1/2Active, not recruitingUnresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1132025-05-23 (+4 mo)
BGB-A445
NCT05661955
P1/2Active, not recruitingUrothelial Carcinoma; Renal Cell Carcinoma1132025-05-27 (+9 mo)
Pamiparib capsule
NCT03519230
P3Active, not recruitingOvarian Cancer2242025-12-01 (+68 mo)
Tislelizumab (BGB-A317)
NCT03736889
P2RecruitingMSI-H/dMMR Solid Tumors2002026-11 (+59 mo)
Tislelizumab
NCT03967977
P3Active, not recruitingUrothelial Carcinoma4202027-06-30 (+60 mo)